Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle

Zhongbing Lu1, John Fassett, Xin Xu

  • 1Center for Vascular Biology, University of Minnesota, Minneapolis, MN 55455, USA.

Circulation
|October 8, 2008
PubMed

Insights

Adenosine protects the heart, but A(3) receptors (A(3)R) counteract this effect. Blocking A(3)R may treat heart hypertrophy and dysfunction caused by pressure overload.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Pharmacology

Background:

  • Endogenous adenosine offers cardioprotection against hypertrophy and heart failure.
  • The specific roles of adenosine A(1) receptors (A(1)R) and A(3) receptors (A(3)R) in this process remain unclear.

Purpose of the Study:

  • To investigate the contribution of A(1)R and A(3)R to cardiac protection during pressure overload.
  • To determine if A(3)R gene deficiency (KO) or A(1)R KO impacts cardiac response to transverse aortic constriction (TAC).

Main Methods:

  • Utilized A(3)R KO and A(1)R KO mouse models subjected to TAC.
  • Assessed left ventricular hypertrophy, fibrosis, cardiac dysfunction, and myocardial stress markers.
  • Examined effects in CD73 KO mice and phenylephrine-induced cardiomyocyte hypertrophy models.
  • Investigated the impact of A(3)R antagonism on adenosine analogue efficacy.

Main Results:

  • Contrary to hypothesis, A(3)R KO attenuated TAC-induced cardiac hypertrophy, fibrosis, and dysfunction.
  • A(3)R KO reduced markers of myocardial stress and hypertrophy.
  • A(1)R KO increased mortality post-TAC but did not affect hypertrophy or dysfunction.
  • Impaired adenosine production (CD73 KO) exacerbated TAC effects; A(3)R antagonism enhanced cardioprotective effects of an adenosine analogue.

Conclusions:

  • Adenosine provides cardiac protection, but A(3)R activity opposes this protective effect.
  • Selective A(3)R attenuation presents a potential therapeutic strategy for pressure overload-induced cardiac hypertrophy and dysfunction.
Abstract

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...